Loading lessons…
Peptide learning paths
Learn peptides step by step
Curated lessons across 8 learning paths — from first concepts to trial summaries and practical protocols. Pick your level, follow the curriculum, and build real understanding.
Where are you starting?
190lessons
8paths
0day streak
0%explored
Start your first lesson
Choose a learning path below or search the library. Progress saves in your browser.
Learning paths
Pick a track — progress rings update as you complete lessons.
18 lessons
9mPeptidesIntermediate
Retatrutide Is Approaching Surgery-Level Weight Loss: What the New Data Actually Means
Retatrutide's weight-loss signal is now strong enough that people are comparing it with surgery. That comparison is useful, but only if you understand what the numbers do and do not mean.
8mPeptidesIntermediate
Amylin and GLP-1: The Next Wave of Metabolic Peptides
The next metabolic peptide wave is not just stronger GLP-1 dosing. Amylin, GIP, glucagon, and combination protocols are changing what serious tracking should include.
8mResearchAdvanced
Retatrutide TRIUMPH-1 Phase 3 Results: How to Track the 28.3% Weight Loss Data
The new TRIUMPH-1 readout gives retatrutide users a clearer dose-response map: 4 mg, 9 mg, and 12 mg all worked, but the tolerability tradeoffs matter.
8mResearchAdvanced
Retatrutide Trials in 2026: Back Pain, Liver, Heart, and Muscle Signals to Watch
Retatrutide is no longer just a weight-loss headline. Current 2026 trial records show researchers testing broader questions: pain, liver disease, cardiorenal risk, dose escalation, and lean-mass preservation.
9mResearchAdvanced
Retatrutide TRIUMPH-4: 28.7% Weight Loss and Osteoarthritis Relief in One Peptide
The TRIUMPH-4 trial delivers groundbreaking dual benefits: 28.7% body weight reduction plus significant osteoarthritis pain relief. Retatrutide's triple mechanism may solve two problems simultaneously.
7mResearchAdvanced
Retatrutide Trial Participant Hit 31% Total Body Weight Loss: What the Number Actually Means
31% body weight loss in a trial participant. Not an average — an individual result. But when 39.4% of Phase 3 participants on the 12mg dose hit the same milestone, the outlier becomes a pattern.
9mResearchAdvanced
Retatrutide Phase 3 Results: 28.7% Weight Loss Sets New Standard
New Phase 3 data shows Retatrutide nearly doubled the weight loss results of current GLP-1 drugs without hitting a plateau.
9mProtocolsIntermediate
Retatrutide Dosing for Beginners: Your First 12-Week Titration Schedule
Retatrutide is one of the most powerful GLP-1/GIP/glucagon receptor agonists available. But starting at the wrong dose — or jumping up too fast — is the #1 beginner mistake. Here's the complete titration roadmap.
9mPeptidesIntermediate
Retatrutide Cuts Knee Pain by 75.8%: What the TRIUMPH-4 Trial Means Beyond Weight Loss
Everyone focused on the 71-pound weight loss stat from TRIUMPH-4. But the buried finding — 75.8% reduction in knee pain scores — may be the more important number for anyone living with joint pain.
10mPeptidesIntermediate
Retatrutide Phase 3 Results: 28.7% Body Weight Reduction Sets a New Standard
Phase 3 trial data is in: retatrutide delivers 28.7% average body weight reduction, outpacing every approved GLP-1 therapy. The numbers tell a clear story about where metabolic medicine is heading.
9mProtocolsIntermediate
Retatrutide: How to Reconstitute and Take Your First Dose
Everything you need to know before your first retatrutide injection — reconstitution math, dose calculations, injection technique, and what to expect if you have prior GLP-1 sensitivity.
10mPeptidesIntermediate
The Science of Retatrutide: How GLP-1/GIP/Glucagon Triple Agonists Work
Retatrutide's triple receptor mechanism simultaneously suppresses appetite, enhances metabolic function, and activates thermogenesis. Here's the science behind why it delivers 24% body weight reduction.
10mPeptidesIntermediate
How Retatrutide Works: The Science Behind the Triple-Receptor Agonist
Retatrutide is not just a stronger tirzepatide. It's a fundamentally different molecule with three receptor targets instead of two. Here's how each mechanism contributes to rapid fat loss, metabolic optimization, and muscle preservation.
12mPeptidesIntermediate
Retatrutide vs Tirzepatide: What the Latest Clinical Data Shows
Retatrutide and tirzepatide dominate the peptide conversation, but they're not interchangeable. Here's what the latest clinical research reveals about their differences, efficacy, and mechanisms.
10mPeptidesIntermediate
Retatrutide Shows 23% Superior Weight Loss vs Tirzepatide in Phase 3 Trial
Retatrutide, the triple-action GLP-1/GIP/glucagon receptor agonist, outperforms tirzepatide by 23% in the latest human clinical trial—the most comprehensive weight loss comparison to date.
10mPeptidesIntermediate
Retatrutide: The Triple-Action Weight Loss Peptide Explained
Retatrutide is a next-generation weight loss peptide targeting three metabolic pathways. Here's how it works and why it outperforms earlier GLP-1 therapies.
9mResearchAdvanced
Retatrutide 2-Year Weight Loss Durability: What the Latest Data Shows
Retatrutide is showing remarkable 2-year durability for weight loss. Here's what the science says and what it means for your protocol.
10mPeptidesIntermediate
Tirzepatide: The Dual Agonist Revolution in Weight Loss
Discover why Tirzepatide's dual mechanism is producing record-breaking weight loss results in clinical trials.
Also available at /blog for legacy links.